In the KEYNOTE 001 study, which assessed pembrolizumab in 655 patients with advanced melanoma, PDL1 expression in pre-treatment tumor biopsy samples correlated with response rate, PFS and OS. This evidence concerns the gene CD274 and neoplasm.